• Gain Therapeutics posted a net loss of $5.61 million, or $0.13 per share, for Q1 2026, narrowing from a per-share loss of $0.16 a year earlier.
• R&D expense rose 21.74% to $2.8 million, while G&A expense climbed 23.81% to $2.6 million.
• Cash, cash equivalents and marketable securities fell to $16.5 million as of March 31, from $20.8 million at Dec. 31.
• GT-02287 Phase 1b nine-month extension fully enrolled with 16 participants; as of March, 14 of 16 had completed five months of dosing, with MDS-UPDRS scores stable over 150 days.
• Management expects FDA clearance of its IND in Q2 2026, plans to start a Phase 2 trial in Q3 2026, and targets Phase 1b results in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110700PRIMZONEFULLFEED9717171) on May 11, 2026, and is solely responsible for the information contained therein.